ArticleCritical care (London, England)2016
The use of angiotensin II in distributive shock.
Article in Critical care (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.American journal of respiratory and critical care medicine · 2020Trial
- Early multimodal vasopressor strategy in septic shock (TRICYCLE)-Study protocol for a randomized controlled clinical trial.PloS one · 2025Article
- Impaired angiotensin II signaling in septic shock.Annals of intensive care · 2024Review
- Angiotensin ii therapy in refractory septic shock: which patient can benefit most? A narrative review.Journal of anesthesia, analgesia and critical care · 2024Review
- Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock.Critical care (London, England) · 2023Observational
- Alternatives to norepinephrine in septic shock: Which agents and when?Journal of intensive medicine · 2022Review
- Why the renin-angiotensin-aldosterone system (RAAS) in critically ill patients can no longer be ignored.Critical care (London, England) · 2021Article
- Review
- Article
- Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.Critical care (London, England) · 2020Article
- Angiotensin converting enzyme defects in shock: implications for future therapy.Critical care (London, England) · 2018Article
- Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.Critical care medicine · 2018Article
- Angiotensin in Critical Care.Critical care (London, England) · 2018Review
- New Insights into the Immune Molecular Regulation of the Pathogenesis of Acute Respiratory Distress Syndrome.International journal of molecular sciences · 2018Review
- Angiotensin II: a new therapeutic option for vasodilatory shock.Therapeutics and clinical risk management · 2018Review
- Perspectives on aetiology, pathophysiology and management of shock in African children.African journal of emergency medicine : Revue africaine de la medecine d'urgence · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.